Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Mar 7, 2022
- Accession no.
- 0000899243-22-009744
- Filed
- Mar 7, 2022, 6:09 PM ET
- Trade date
- Mar 3-7, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $344.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | Director, 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | Director, 10% Owner |
| Boyd StevenCIK 0001706140 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2022 | Common Stock | PPurchaseAcquired | +50,000 | $0.7139 | +$35,695 | 46,890,000 | Indirect | |
| Mar 4, 2022 | Common Stock | PPurchaseAcquired | +135,000 | $0.7045 | +$95,107.5 | 47,025,000 | Indirect | |
| Mar 7, 2022 | Common Stock | PPurchaseAcquired | +325,000 | $0.6564 | +$213,330 | 47,350,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.